Adjuvants enhance the body's immune response by triggering and regulating innate and adaptive immunity. CD BioGlyco has committed to developing carbohydrate adjuvants for many years and we are pleased to share our knowledge and experience to advance your adjuvant research.
Compared with traditional vaccines, subunit vaccines based on homologous antigens have the advantages of precise targeting and improved safety. The vaccines require adjuvants to enhance the immunogenicity of the antigen for optimal vaccine efficacy. However, the mechanisms by which adjuvants enhance immune responses are poorly understood in humans. This phenomenon has hindered the development of the vaccine field. Aluminum salts have been approved for use in human vaccines as the only adjuvant for over 70 years. Therefore, there is an urgent need to develop novel, potent, and less toxic adjuvants to enhance the immunogenicity of subunit vaccines.
Carbohydrates are the most widely distributed biological macromolecules in nature and have the advantages of good biocompatibility, strong tolerance, and high safety. In addition, they also play a key role in immune regulation. Currently, many carbohydrates derived from plants, bacteria, and yeast have been evaluated as potential candidate adjuvants. For example, Deltin adjuvant is effective in animal models of human immunodeficiency virus (HIV) vaccines, avian influenza (H5N1) vaccines, Japanese encephalitis vaccines, and African equine disease vaccines. Now, the adjuvant is in the clinical research stage for human hepatitis B and antiviral vaccines.
Based on the advantages of carbohydrates and their application potential in the field of adjuvant, CD BioGlyco provides high-quality carbohydrate-based adjuvant development services to meet customers' needs. Our adjuvant development services include lipopolysaccharide, bacterial outer membrane vesicles (OMVs), trehalose glycolipid, galactosylceramide, peptidoglycan, chitin/chitosan, inulin, mannans, alginate, saponin, α-glucan, lentinan, β-glucans, Deltin, muramyldipeptide, cord factor, zwitterionic polysaccharides, and novel plant polysaccharides.
We have developed multiple strategies to help our clients design and develop lipopolysaccharide-based adjuvants to enhance the body's immune activity.
We provide customers with the development service of bacterial homologous OMVs adjuvant, bacterial heterologous OMVs adjuvant, and click-OMVs adjuvant.
Trehalose glycolipid is a promising vaccine adjuvant. We offer trehalose monoester glycolipid and trehalose diester glycolipid adjuvant development services.
CD BioGlyco provides customized galactosylceramide-based adjuvant development services according to the specific needs of our global customers.
We have established an advanced carbohydrate adjuvant development platform to help customers develop peptidoglycan-based adjuvants.
CD BioGlyco provides high-quality chitin/chitosan-based adjuvant development services for anti-influenza A, anti-hepatitis B, anti-Helicobacter pylori, etc.
CD BioGlyco has developed high-quality inulin-based adjuvants that can be used in a variety of vaccines, such as hepatitis B vaccine, influenza vaccine, anthrax vaccine, etc.
CD BioGlyco is a leader in developing mannans-based carbohydrate adjuvantsto enhance the body's humoral and cellular immunity.
Alginate has great application potential in vaccine adjuvants. We provide high-quality alginate-based adjuvant development services.
We offer a variety of synthetic saponin variant adjuvant development services by chemical derivatization of natural products or new saponin analogs.
Compounds derived from natural products have great advantages in immunomodulation. We provide plant-derived α-glucan adjuvant development service.
CD BioGlyco provides custom lentinan-based adjuvant development services according to each specific need of our global clients. Welcome to consult us about it!
β-Glucan can be used in adjuvant and vaccine delivery platforms. CD BioGlyco provides development services for various β-glucan adjuvant and their modified variants.
Based on our advanced Glyco™ Vaccine Development Platform, we provide development service of Deltin adjuvant against different types of antigens.
CD BioGlyco provides customers with adjuvant development services for muramyldipeptide and its derivatives to enhance the body's immune response.
At present, many analogs of cord factor have been synthesized. CD BioGlyco offers custom cord factor-based adjuvant development services to customers.
CD BioGlyco provides new zwitterionic polysaccharide conjugate adjuvant development services by chemically modifying native bacterial polysaccharides.
CD BioGlyco provides our customers with high-quality, cost-effective, and hassle-free adjuvant development services. If you are interested in our services, please contact us directly. We are looking forward to being your indispensable assistant in adjuvant development.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.